PARP inhibitors plough on
Nature Reviews Drug Discovery 16, 229 (2017).
doi:10.1038/nrd.2017.61
Author: Asher Mullard
New clinical data for AstraZeneca's first-in-class poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has raised the bar for a bevy of would-be competitors.The FDA granted accelerated approval to olaparib in 2014 for fourth-line treatment of BRCA-mutated ovarian cancer, but the drug came under pressure last
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
More News: AstraZeneca | Cancer | Cancer & Oncology | Drugs & Pharmacology | Ovarian Cancer | Ovaries